Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
Dermatol Ther. 2022 Dec;35(12):e15866. doi: 10.1111/dth.15866. Epub 2022 Oct 13.
Adalimumab is the only biological drug approved to date for the treatment of moderate and/or severe hidradenitis suppurativa. Adverse events reported during therapy include paradoxical psoriasiform reactions. No guidelines are currently available for the management of this clinical condition. The aim of this paper is to describe the incidence and clinical features of paradoxical psoriasiform eruptions occurring during treatment with adalimumab in patients with hidradenitis suppurativa and to report real-life experience in management and the possible role of other biologic agents for the treatment of both conditions.
阿达木单抗是迄今为止唯一被批准用于治疗中重度化脓性汗腺炎的生物药物。治疗过程中报告的不良反应包括矛盾性银屑病样反应。目前尚无针对这种临床情况的管理指南。本文旨在描述阿达木单抗治疗化脓性汗腺炎患者时发生矛盾性银屑病样发作的发生率和临床特征，并报告在管理方面的真实经验以及其他生物制剂在治疗这两种疾病中的可能作用。
